Hellmén, Eva
- Institutionen för husdjurens biovetenskaper, Sveriges lantbruksuniversitet
Forskningsartikel2017Vetenskapligt granskad
Gelaleti, G. B.; Borin, T. F.; Maschio-Signorini, L. B.; Moschetta, M. G.; Hellmen, E.; Viloria-Petit, A. M.; Zuccari, D. A. P. C.
Background: Melatonin has oncostatic actions and IL-25 is active in inflammatory processes that induce apoptosis in tumor cellsAim: The aim of this study was to evaluate melatonin and IL-25 in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumor cells cultured as monolayers and tridimensional structures.Materials and Methods: The cells were treated with melatonin, IL-25 and IL-17B silencing gene and performed cell viability, gene and protein expression of caspase-3 and VEGFA (Vascular endothelial growth factor A) and an apoptosis membrane protein array.Results: Treatment with 1 mM of melatonin reduced cell viability of both tumor cell lines, all treatments alone and combined significantly increased caspase-3 cleaved and proteins involved in the apoptotic pathway and reduced pro-angiogenic VEGFA, confirming the effectiveness of these potential promising treatments.Conclusion: This is the first study evaluating the potential use of these strategies in CF-41 and CMT-U229 cell lines and together encourages subsequent in vitro and in vivo studies for further exploration of clinical applications.
angiogenesis; apoptosis; canine; interleukin-25; melatonin; mammary tumour cells
Veterinary and Comparative Oncology
2017, Volym: 15, nummer: 4, sidor: 1572-1584
Medicinsk biovetenskap
DOI: https://doi.org/10.1111/vco.12303
https://res.slu.se/id/publ/91977